Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr

Environmental Health and Preventive Medicine

Volumn 17, Issue 3, 2012, Pages 173-182

  Kitamori, Kazuya ^a,b   Naito, Hisao ^a   Tamada, Hazuki ^a,b   Kobayashi, Miya ^b   Miyazawa, Daisuke ^b   Yasui, Yuko ^b   Sonoda, Kunihiro ^b   Tsuchikura, Satoru ^c   Yasui, Naomi ^d   Ikeda, Katsumi ^d   Moriya, Takashi ^a   Yamori, Yukio ^d   Nakajima, Tamie ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINJO GAKUIN UNIVERSITY   (Japan)

^c Disease Model Cooperative Research Association   (Japan)

^d MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

Author keywords

Fibrosis; High fat and highcholesterol containing diet; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; SHRSP5 Dmcr

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; COLLAGEN; GAMMA GLUTAMYLTRANSFERASE; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID DIET; LIPID METABOLISM; LIVER CELL; LIVER FIBROSIS; LIVER FUNCTION; LIVER NECROSIS; LIVER WEIGHT; LYMPHOCYTIC INFILTRATION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT;

ADIPONECTIN; ALBUMINS; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, DIETARY; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; GAMMA-GLUTAMYLTRANSFERASE; INSULIN; LIVER; LIVER CIRRHOSIS; MALE; RATS; RATS, INBRED SHR; TRANSAMINASES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

ANIMALIA; RATTUS;

EID: 84862891065     PISSN: 1342078X     EISSN: 13474715     Source Type: Journal    
DOI: 10.1007/s12199-011-0235-9     Document Type: Article

References (39)

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-50.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116: 1413-9.
3. Shimada M, Hashimoto E, Taniai M, Hasegawa K, Okuda H, Hayashi N, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Hepatol. 2002;37:154-60.
4. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, Tokushige K, et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol. 2009;44:89-95.
5. Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005;11:255-9.
6. Hashimoto E, Yatsuji S, Kaneda H, Yoshioka Y, Taniai M, Tokushige K, et al. The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 2005;33:72-6.
7. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, et al. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology. 2007;46:1392-403.
8. Cong WN, Tao RY, Tian JY, Liu GT, Ye F. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sci. 2008;82:983-90.
9. Ip E, Farrell G, Hall P, Robertson G, Leclercq I. Administration of the potent PPARalpha agonist, Wy-14, 643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004;39: 1286-96.
10. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007;128:837-47.
11. Tseng PH, Liu CJ, Kao JH, Shun CT, Chen PJ, Chen DS. Disease progression in a patient with nonalcoholic steatohepatitis. J Formos Med Assoc. 2008;107:816-21.
12. Li CH, Piao DM, Xu WX, Yin ZR, Jin JS, Shen ZS. Morphological and serum hyaluronic acid, laminin and type IV collagen changes in dimethylnitrosamine- induced hepatic fibrosis of rats. World J Gastroenterol. 2005;11:7620-4.
13. Son G, Iimuro Y, Seki E, Hirano T, Kaneda Y, Fujimoto J. Selective inactivation of NF-kappaB in the liver using NFkappaB decoy suppresses CCl4-induced liver injury and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G631-9.
14. Wang XH, Zhao J, Zhang WG, Zhang LY, Ma RQ, Wang LQ, et al. Scanning electron microscopic observation: three-dimensional architecture of the collagen in hepatic fibrosis rats. Chin Med J (Engl). 2007;120:308-12.
15. Yamori Y. Selection of arteriolipidosis-prone rats (ALR). Jpn Heart J. 1977;18:602-3.
16. Yamori Y, Kitamura Y, Nara Y, Iritani N. Mechanism of hypercholesterolemia in arteriolipidosis-prone rats (ALR). Jpn Circ J. 1981;45:1068-73.
17. Sansawa H, Takahashi M, Tsuchikura S, Endo H. Effect of chlorella and its fractions on blood pressure, cerebral stroke lesions, and life-span in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol. 2006;52:457-66.
18. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-509.
19. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21.
20. Elias J Jr, Altun E, Zacks S, Armao DM, Woosley JT, Semelka RC. MRI findings in nonalcoholic steatohepatitis: correlation with histopathology and clinical staging. Magn Reson Imaging. 2009;27:976-87.
21. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467-74.
22. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007;381: 107-13.
23. Fisher CD, Lickteig AJ, Augustine LM, Oude Elferink RP, Besselsen DG, Erickson RP, et al. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur J Pharmacol. 2009;613: 119-27.
24. Zatloukal K, FrenchSW, Stumptner C, Strnad P, Harada M, Toivola DM, Cadrin M,Omary MB. From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res. 2007;313(10):2033-49.
25. Musso G, Gambino R, De Michieli F, Cassader M, Rizzetto M, Durazzo M, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909-16.
26. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLDClinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology. 2009;49:809-20.
27. Collison M, Glazier AM, Graham D, Morton JJ, Dominiczak MH, Aitman TJ, et al. Cd36 and molecular mechanisms of insulin resistance in the stroke-prone spontaneously hypertensive rat. Diabetes. 2000;49:2222-6.
28. Oakley F, Mann J, Nailard S, Smart DE, Mungalsingh N, Constandinou C, et al. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. Am J Pathol. 2005;166:695-708.
29. Watanabe S, Horie Y, Kataoka E, Sato W, Dohmen T, Ohshima S, et al. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice. J Gastroenterol Hepatol. 2007;22:S96-100.
30. Ishii H, Horie Y, Ohshima S, Anezaki Y, Kinoshita N, Dohmen T, et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice. J Hepatol. 2009;50:562-71.
31. Sazci A, Akpinar G, Aygun C, Ergul E, Senturk O, Hulagu S. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig Dis Sci. 2008;53:3218-24.
32. Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366-74.
33. Fu CC, Chen MC, Li YM, Liu TT, Wang LY. The risk factors for ultrasound-diagnosed non-alcoholic fatty liver disease among adolescents. Ann Acad Med Singap. 2009;38:15-21.
34. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46:1081-90.
35. Caballero F, Fernández A, De Lacy AM, Fernández-Checa JC, Caballería J, García-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 2009;50: 789-96.
36. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-62.
37. Moriya T, Naito H, Ito Y, Nakajima T. "Hypothesis of seven balances": molecular mechanisms behind alcoholic liver diseases and association with PPARalpha. J Occup Health. 2009;51(5): 391-403.
38. Yun JW, Shin ES, Cho SY, Kim SH, Kim CW, Lee TR, et al. The effects of BADGE and caffeine on the time-course response of adiponectin and lipid oxidative enzymes in high fat diet-fed C57BL/6 J mice: correlation with reduced adiposity and steatosis. Exp Anim. 2008;57(5):461-9.
39. Duval C, Thissen U, Keshtkar S, Accart B, Stienstra R, Boekschoten MV, et al. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes. 2010;59(12):3181-91.